Adenovirus complex for gene delivery and gene iherapy
View Patent ↗The present invention relates to an adenovirus complex which can be utilized for gene delivery and gene therapy by targeting neurotensin receptors. The complex of the present invention has an excellent antitumor effect because of a high intracellular gene transfer efficiency and target specificity by neurotensin receptor-specific binding, has little hepatotoxicity and immunogenicity, forms a stable complex, has low immunogenicity, and thus has a low loss in blood even in an in vivo environment. Therefore, the complex of the present invention can be effectively used for gene therapy.
1. A gene delivery system, comprising:
an adenovirus (Ad), polyethylene glycol (PEG) and a neurotensin receptor-specific binding peptide (NT), wherein the NT is conjugated with the PEG to form PEG-NT conjugate, and the PEG is conjugated to the surface of the Ad capsid with a crosslinker; and
wherein the Ad is conjugated with the PEG-NT conjugate in the ratio of 1 mol:1×10 4 -1×10 6 mol.
2. The gene delivery system of claim 1 , wherein the crosslinker is 3,3′-dithsiobis(sulfosuccinimidyl propionate) (DTSSP), and the Ad is conjugated with DTSSP at the ratio of 1 mol:1×10 5 to 3×10 5 mol.
3. The gene delivery system of claim 1 , wherein the NT consists of the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence of SEQ ID NO: 2.
4. The gene delivery system of claim 1 , wherein the Ad further comprises one or more target genes.
5. A complex for gene therapy comprising:
an adenovirus (Ad), polyethylene glycol (PEG), a neurotensin receptor-specific binding peptide (NT), and chemical therapeutic drugs,
wherein the chemical therapeutic drugs are conjugated with the PEG, the NT is conjugated with the PEG to form PEG-NT conjugate, and the PEG is conjugated to the surface of the Ad capsid with a crosslinker, and
wherein the Ad is conjugated with the PEG-NT conjugate in the ratio of 1 mol:1×10 4 -1×10 6 mol.
6. A complex for gene therapy comprising:
an adenovirus (Ad), polyethylene glycol (PEG), and a neurotensin receptor-specific binding peptide (NT),
wherein the Ad comprises a therapeutic gene, and
wherein the NT is conjugated with the PEG to form PEG-NT conjugate, and the PEG is conjugated to the surface of the Ad capsid with a crosslinker, and
wherein the Ad is conjugated with the PEG-NT conjugate in the ratio of 1 mol:1×10 4 -1×10 6 mol.
7. The complex of claim 6 , wherein the therapeutic gene comprises the nucleotide sequence of a decorin gene and the nucleotide sequence of SEQ ID NO: 3 encoding a Wnt3a/β-catenin signaling inhibitory protein.
8. A method for preparing a gene delivery system or a complex for gene therapy, comprising:
reacting an adenovirus (Ad) with a crosslinker 3,3′-dithiobis(sulfosuccinimidyl propionate) (DTSSP) at the ratio of 1 mol:1×10 5 to 3×10 5 mol to conjugate the crosslinker to the surface of the Ad capsid;
preparing a polyethylene glycol-neurotensin receptor-specific binding peptide (PEG-NT) conjugate by reacting the PEG and NT; and
preparing an Ad-PEG-NT conjugate by reacting the Ad and the PEG-NT conjugate, and wherein the Ad is conjugated with the PEG-NT conjugate in the ratio of 1 mol:1×10 4 -1×10 6 mol.